News Release
More-
September 24, 2024
Succession of Manufacturing and Marketing Authorization for MARIZEV®, Diabetes Treatment -
September 17, 2024
Launch of YSELTY® (generic name linzagolix) for uterine fibroid treatment in Europe -
September 9, 2024
Drug discovery research collaboration agreement with Reborna Biosciences, Inc. -
September 4, 2024
Licensing Agreement for "olutasidenib", an Acute Myeloid Leukemia Drug -
July 16, 2024
Results of a Japan Phase III Clinical Trial of the GnRH Antagonist Linzagolix in Patients with Uterine Fibroids - Primary Endpoint has been Achieved -
Topics
More-
July 30, 2024
The First Quarter of FY2024 (July 30, 2024) -
July 30, 2024
R&D Pipeline as of July 2024 -
June 28, 2024
Status of Dialogue with Shareholders and Investors (June 28, 2024) -
May 7, 2024
Financial Results (May 7, 2024) -
January 30, 2024
The Third Quarter of FY2023 (January 30, 2024)
